The paired filings confirm a coordinated, aggressive sell-down by a founding venture investor after a significant stock run (KYMR at ~$9.4B cap with 93% analyst buy rating). Institutional holders should watch for continued secondary distribution, these filings are 'intent to sell' notices, and the trailing realized sales suggest the selling is already underway. The concentration risk from a top holder reducing positions suggests near-term overhang; traders may consider reducing exposure or hedging until the distribution cadence slows.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $109.32entry
- T+1 · 5mo ago +4.89%α +4.12% · $114.67
- T+5 · 4mo ago +4.98%α +3.59% · $114.76
- T+20 · 4mo ago +1.14%α +1.42% · $110.57
- T+60 · 8w ago +11.65%α +7.27% · $122.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. filed paired Form 144 notices on June 26, 2026, signaling intent to sell a combined 467,878 shares of Kymera Therapeutics common stock worth approximately $54.8 million. The filings reveal a coordinated sell-down by a founding venture capital investor alongside an Atlas-affiliated individual (Bruce Booth), with substantial prior sales executed over the preceding week (June 17–25) totaling ~1.1M shares.
Key Facts
- Atlas Venture Fund X, L.P. filed Form 144 to sell 410,427 shares valued at ~$47.8 million.
- Atlas Venture Opportunity Fund I, L.P. filed Form 144 to sell 57,451 shares valued at ~$6.7 million.
- Combined proposed sale: 467,878 shares worth approximately $54.8 million based on filing price.
- Atlas entities had already sold ~1,058,130 shares in the prior week (June 17–25) for ~$117.2 million, based on transaction detail reported in the filings.
- Bruce Booth, an Atlas-affiliated individual, also participated in prior-week sales of 23,900 shares (approx. $2.2 million).
- Shares were acquired via private placement in March 2020 pre-IPO, representing control/restricted securities.
- The filers are a top-2 institutional holder (Baker Bros. and Avoro Capital are also top holders per 13F data), making this a material reduction by a founding investor.
- Recent 30-day insider activity already showed $10M in sales prior to these filings.
- Market cap of ~$9.4B makes the proposed ~$55M sale ~0.6% of market cap, but the trailing week's realized sales of ~$117M represent ~1.2%.
- Atlas Venture Fund X alone previously sold ~1,038,500 shares in the prior week, signaling aggressive distribution.
Financial Impact
Proposed sales of ~$54.8M, with trailing week realized sales of ~$117M, bringing total disclosed near-term Atlas distribution to ~$172M. This represents meaningful insider liquidation by a founding venture backer.
Risk Factors
- Continued secondary selling by other insiders or early investors following Atlas's lead.
- Supply overhang from the ~$55M proposed sale, which could pressure near-term price action.
- Atlas is a high-conviction early investor, their liquidation may signal a peak valuation view or portfolio rebalancing, but could also be fund-cycle driven.
- Potential for additional Form 144 filings as Atlas continues its distribution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (KYMR), Batch item 1 | 0001628280-26-045808 |
| Document: 0001628280-26-045808-index.html | 0001628280-26-045807 |
| Document: 0001628280-26-045808.txt | 0001628280-26-045808 |
| 144 Filing (KYMR), Batch item 4 | 0001628280-26-045807 |
| Document: 0001628280-26-045807-index.html | 0001628280-26-045808 |
| Document: 0001628280-26-045807.txt | 0001628280-26-045808 |
Track record
37 reports on KYMR
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers